News
Two projects from Celon Pharma’s innovative portfolio at the American Psychiatric Association Annual Meeting 2018
During a poster session which will take place on 7 and 8 May 2018 at the Representatives of the American Psychiatric Association Annual Meeting CNS Research Group, representatives of the CNS Research Group will present two projects from the Company’s innovative portfolio. The sessions will be run by Mikołaj Matłoka – Leader of the CNSRead more »
Celon Pharma S.A. reports a solid profit for 2017, gaining momentum in its quest towards the global market of innovative pharmaceutics
107 million of sales income in 2017, enhancing the Company’s position on the Polish pharmaceutical market with an over 11% sale growth in terms of volume and4.3% in terms of value. 7 million of export sales with a significant growth potential covering new European countries in the coming months. Net profit for 2017 – 25.6Read more »
The application for a consent to commence phase I of a clinical trial on the FGFR kinase inhibitor has been submitted
Celon Pharma S.A. has finalised the preclinical phase and has submitted an application to the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for the consent to commence the next stage of the trial, i.e. the clinical phase. Phase I of the CLP304110 trial is a multicentre trial carriedRead more »
Maciej Wieczorek in Poland Healthcare&Life Sciences Review – an interview
President of the Company, Maciej Wieczorek, about Celon’s business plans and the perspectives of development of the Polish biotech industry in an interview given to Poland Healthcare & Life Sciences Review Pharmaceutical Executive Magazine. We encourage you to read the interview.
Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants
Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: Participants receivedRead more »
Celon Pharma S.A. at EIT Health Matchmaking
250 participants: scientists and entrepreneurs, 3 days of debates and meetings on the most important challenges in the area of health and innovation in Europe, including representatives of Celon Pharma. The biggest meeting of this year was aimed at developing the main pillars of the EIT Health agenda in 2018/2019. Jerzy Pieczykolan, PhD, Head ofRead more »
Maciej Wieczorek, at the Impact CEE conference, talking about financing the Polish biotechnology industry and its future
Maciej Wieczorek, CEO was a guest of the Impact CEE conference . A series of such meetings is attended by representatives of national research institutes, Polish and international companies, the public administration and representatives of start-ups. The subject of the first debate was the biotech industry, it took place on 19 February 20118 at theRead more »
Maciej Wieczorek among the 100 most influential people in Polish healthcare in 2017
Yet another year in a row, Maciej Wieczorek was ranked on the 100 most influential people in Polish healthcare in 2017 list prepared by Puls Medycyny. The ranking was announced on 5 February this year. The editors of Puls Medycyny presented the judges with over 300 nominees for evaluation. The jury panel was composed ofRead more »
Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials
Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »